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Abstract Our goal was to determine the epidemiology of
severe varicella-zoster virus (VZV) infections in hospi-
talised paediatric patients. Admissions associated with
VZV infection of patients aged 0–16 years were reported
by all 38 paediatric units in Switzerland to the Swiss
Paediatric Surveillance Unit (SPSU) during 3 consecu-
tive years (4/2000–3/2003). We veriﬁed completeness of
reporting by capture-recapture analysis with patient
records identiﬁed by ICD-10 codes. Outcome of illness
was assessed 6 months after hospitalisation. A total of
335 cases (235 identiﬁed by SPSU reports, 100 by ICD-
10 code) were included in this study. Mean age of pa-
tients was 4.1 years (median 3.5 years, range 0–16
years); 54% were male. Some 293 (87%) patients pre-
sented with chickenpox, 42 (13%) with herpes zoster
and 291 (87%) patients were not immunocompromised.
A total of 319 complications occurred in 237 (71%)
patients: secondary bacterial infections (n=109); central
nervous system involvement (n=76); VZV pneumonitis
(n=7); others (n=127). Eleven (3%) patients required
intensive care and three died. On follow-up, 303 (96%)
of 315 patients had completely recovered; sequelae were
present in 12 (4%) patients. The calculated hospitalisa-
tion rate was 13 per 104 cases. Conclusion: This study
describes a sizeable hospitalisation and complication
rate of varicella-zoster virus infections and provides a
solid basis for future immunisation recommendations in
Switzerland.
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Introduction
In Switzerland, immunisation against varicella-zoster
virus (VZV) has not been generally recommended and
no speciﬁc recommendations for use of varicella vaccine
existed in Switzerland when this study was performed,
despite the availability of a safe and eﬀective live
attenuated vaccine for many years.
The range and severity of VZV infection compli-
cations in childhood have been described in several
studies [3, 4, 9, 10, 11, 12, 16, 17, 18, 19, 22, 24,25].
However, there are considerable diﬀerences between
studies regarding the frequency of complications and
hospitalisation rates. This might be due to variability
in methods of data collection and analysis, geo-
graphical settings, living conditions, and admission
policies.
The goal of our study was to generate data on vari-
cella-associated morbidity in Switzerland as a basis for
national immunisation recommendations. We aimed to
determine hospitalisation rate, complication rate, dif-
ferences between immunocompromised and immuno-
competent patients, and the role of bacterial pathogens
in paediatric patients with active VZV infection by
prospective data collection and validation of reporting
completeness by use of a second independent data
source.
This study was presented in part at the 42nd Interscience Confer-
ence on Antimicrobial Agents and Chemotherapy (ICAAC), San
Diego, September 27th–30th, 2002
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Subjects and methods
Case deﬁnition
We deﬁned active VZV infection as ‘‘typical varicella
rash or herpes zoster diagnosed by a physician and
occurring within 30 days prior to or during hospitali-
sation in a patient aged 0–16 years’’.
Swiss Paediatric Surveillance Unit surveillance
The Swiss Paediatric Surveillance Unit (SPSU) was
established in 1995 to assess the epidemiology of selected
childhood diseases leading to hospitalisation. The study
period for VZV infections was April 1, 2000 toMarch 31,
2003. Each month a reporting form was mailed to all 38
paediatric units in Switzerland. Following each report of
a case, one of the investigators (JB, GB, BM) visited the
respective unit and completed a standardised question-
naire (available from the authors on request) together
with the attending paediatrician. Six months after hos-
pital admission, we sent a follow-up questionnaire to the
initial reporter who reported on any subsequent hospi-
talisations and the ﬁnal outcome of the VZV infection.
Performance of SPSU projects is in accordance with
data protection guidelines of all participating paediatric
units.
Patients identiﬁed by ICD-10 code
To evaluate completeness of SPSU reporting and to
reﬁne incidence estimates, we performed a capture-re-
capture analysis. The second independent data source
was medical records of children admitted to 13 repre-
sentative hospitals during the study period. Cases were
identiﬁed by 46 ICD-10 codes (list available from the
authors on request) for VZV infection, potentially VZV-
associated complications, or both.
We reviewed all pertinent records and extracted data
of hospitalisations that had not been reported via the
SPSU and met the case deﬁnition for active VZV
infection using the standardised questionnaire. The 6-
month follow-up investigation was also performed as
described above.
Analysis
Statistical analyses were performed with the SPSS 11.0.0
program (SPSS Inc., Chicago, IL, USA). Independent
proportions were compared by the Pearson v-squared
test. P values <0.05 were considered signiﬁcant. Data
on the general population during the study period were
obtained from the Federal Oﬃce of Statistics [20].
Capture-recapture analysis was calculated based on the
Chapman-Wittes adjustment of the Lincoln-Petersen
maximum likelihood estimate [7].
Results
General population
During the study period, the mean number of children
and adolescents aged 0–16 years in Switzerland was
1,337,175. We calculated the annual number of varicella
cases in this cohort to be 77,084 (based on the estab-
lished VZV antibody prevalence of 98% at the age of 16
years) [1].
Hospitalisation rate
Compliance of paediatric units with returning postcards
to the SPSU was 99% during the study period. A total
of 335 patients fulﬁlled the case deﬁnition; 235 (70%)
were reported to the SPSU and 100 additional patients
(30%) were identiﬁed by ICD-10 codes (Fig. 1).
We performed a capture-recapture analysis on 261
cases identiﬁed from those units for which data of both
independent sources were available (Table 1). The
completeness of SPSU reporting and ICD code identi-
ﬁcation was 0.56 and 0.79, respectively (P =0.54).
Therefore, we assumed 44% underreporting to the
SPSU and estimated the true number of all hospitalised
patients in association with active VZV infection to be
420 (18 per 104 cases) and those caused by VZV infection
to be 305 (13 per 104 cases). Of 420 estimated cases
associated with active VZV infection, 296 (13 per 104
cases) were due to primary varicella and the remaining
124 cases were due to herpes zoster.
Age-speciﬁc hospitalisation rates of primary varicella
were calculated and found to be highest in children up to
4 years of age (Table 2).
Study population
Of the 335 hospitalised patients identiﬁed in this study,
180 (54%) were male, 44 (13%) were immunocompro-
mised, and none of them had been immunised against
varicella. The mean age of the patients was 4.1 years
(median 3.5 years; range 0–16 years) and infants 0 to 12
months old (n=61; 18%) represented the largest single
age group. Mean time from onset of rash to hospitali-
sation was 5 days (median 5 days; range -9 to 27 days)
and mean duration of hospitalisation was 8 days (med-
ian 5 days; range:1–243 days). Herpes zoster was rela-
tively more common in immunocompromised (41%)
than in immunocompetent patients (8%; P <0.001).
Antiviral therapy had been administered to 43 (97%) of
44 immunocompromised and 52 (18%; P <0.001) of
291 immunocompetent patients.
Overall, 319 complications attributable to VZV
infection were noted. Notably, there was no signiﬁcant
diﬀerence in complication rates between the two data
sources. Type and frequency of the 303 complications
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occurring in those 253 patients (including 40 infants)
who were hospitalised due to VZV infection (group 1 in
Fig. 1) is shown in Table 3. The remaining ten and six
complications occurred in 16 patients from group 2 and
in 66 patients from group 3, respectively.
Of 335 patients, 11 (3%) required intensive care
treatment. All of them were immunocompetent, their
median age was 5 years (mean 5.5 years, range 0–14
years), eight were hospitalised due to varicella infection
(group 1), and three primarily for other reasons (group
3). Group 1 cases were admitted to the ICU due to severe
haemorrhagic varicella (n=1), pneumonia (n=1), septic
arthritis and toxic shock syndrome (n=1), congenital
varicella with encephalitis (n=1), meningo-encephalitis
(n=2), pneumococcal sepsis (n=1), and varicella pneu-
monitis (n=1). Group 3 cases were admitted for gener-
alised seizures (n=2) and aspiration pneumonia (n=1).
Three (1%) patients died. Two deaths were attribut-
able to VZV infection in immunocompetent patients
(one due to pneumococcal sepsis and one due to
encephalitis) and one death was caused by cerebral
haemorrhage caused by a coagulation disorder in the
light of an underlying leukaemia rather than VZV
infection. Accordingly, the case fatality rate of hospita-
lised VZV infections was 0.5% and that of all VZV
infections in Switzerland during the study period was
calculated to be 1 in 100,000.
In 103 patients with 109 secondary bacterial infec-
tions, 65 blood cultures, 11 cerebrospinal ﬂuid cultures,
four urine cultures, and 43 tissue cultures were per-
formed. A total of 51 cultures grew bacteria, of which 21
were group A beta-haemolytic streptococci and 17 were
Staphylococcus aureus. Of note, one case of pneumo-
coccal and two cases of meningococcal sepsis occurred.
Follow-up
Follow-up information was available in 231 (98%) cases
reported to the SPSU and in 84 (84%) of those identiﬁed
by ICD-10 code. Seven patients required further hospi-
talisations due to VZV infections or complications
thereof and 12 patients (4%), of whom 11 were immu-
nocompetent, suﬀered from sequelae: disﬁguring scar-
ring (n=9), developmental retardation (n=1), joint
cartilage destruction (n=1), and reduced lung capacity
following pneumonia (n=1).
Discussion
We prospectively determined the spectrum and fre-
quency of complications caused by VZV infections in
children and adolescents in Switzerland during a 3-year
period. While such data have been obtained by a
similar approach in Germany and Canada [12,25], this
Fig. 1 Proﬁle of study population.*Group 1 (n=253; 76%):
patients admitted only due to VZV infection. Group 2 (n=16;
5%): patients admitted due to combination of VZV infection and
concomitant other diseases. Group 3 (n=66; 20%): patients
primarily admitted for diseases other than the VZV infection
Table 1 Capture-recapture analysis of hospitalisations associated
with active VZV infectiona
Identiﬁed by
ICD-10
Reported by
the SPSU
Total (n)
Yes (n) No (n)
Yes 126 100 226
No 35 28b 63
Total 161 128 289
aBased on 261 cases from paediatric units for whom original source
and analytical source data where available
bUndiscovered cases calculated by capture-recapture analysis
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is the ﬁrst prospective nation-wide study where source
completeness was validated by two independent data
sources.
We trust that we determined the true hospitalisation
rate and spectrum of complications amongst hospita-
lised patients, since (1) the active surveillance system
involved all paediatric units in Switzerland, (2) every
single report was thoroughly validated, (3) the data set
was supplemented by a search of further cases using a
broad range of ICD-10 codes in a sample of 13 repre-
sentative paediatric units, (4) comparison of the two
data sources showed no signiﬁcant diﬀerence in com-
plication rates between the two sources (i.e. no evidence
for reporting bias of severe cases to the SPSU), and (5)
capture-recapture analysis showed that both data
sources were independent because the product of the
probabilities of being reported to the SPSU and
being identiﬁed by an ICD-10 code was equal to the
probability of appearing in both sources (0.43).
Hospitalisation rates are widely used as surrogate
measures for disease severity [3, 4, 10, 11, 12, 16, 17, 19,
24, 25]. We aimed to improve this estimate by capture-
recapture analysis and performed this analysis by use of
a representative sample of paediatric units, therefore
potential selection bias should be minimal. The esti-
mated hospitalisation rate for primary varicella was 13
per 104 cases. Whereas this is in the range of reported
rates, it is considerably higher than those in the only two
other prospective studies, i.e. 1 and 5 per 104 cases,
respectively [12, 25].
Age-speciﬁc hospitalisation rates vary between stud-
ies and generally peak in children of 1–4 years of age as
they did in our study [3, 4, 5, 6, 14, 24, 25]. Also, 50% of
all cases occurred in this age group. This underlines the
importance of early immunisation if prevention of
varicella complications is the goal. Interestingly, 18% of
patients were infants and 4% were younger than 3
months of age. This suggests insuﬃcient levels of
Table 2 Age-speciﬁc numbers of primary VZV infections leading to hospitalisation (group 1) during the 3-year study period
Age group
(years)
Sero-prevalence
increasea (%)
Number of
cases
(estimated)
Number of cases
hospitalised
Number of cases
hospitalised
(capture-recapture
estimate)
Age-speciﬁc
hospitalisation
rateb
<1 11 25,957 38 55 21
1–4 27 63,712 117 148 23
5–9 49 115,626 58 80 7
10–16 11 25,957 8 13 5
Total 98 231,252 221 296 13
aFrom age group to age group; based on age-speciﬁc anti VZV-IgG seroprevalence in Switzerland [1]
bPer 104 cases, based on capture-recapture estimates from this study
Table 3 Type and frequency of
complications in 253 patientsa
admitted due to VZV infection
(group 1)
aPatients may have experienced
more than one complication
Complication Total Immunocom-
petent
Immuno-
compromised
N % N % N %
Secondary bacterial infections 109 36 104 37 5 26
Skin infection 65 21 62 22 3 16
Soft tissue infection 8 3 8 3 0 0
Invasive infections 36 12 34 12 2 10
Bacterial pneumonia 12 11 1
Sepsis 9 8 1
Acute osteomyelitis 6 6 0
Septic arthritis 6 6 0
Meningitis 2 2 0
Nephritis 1 1 0
Central nervous system involvement 75 25 72 25 3 16
Meningo-encephalitis 21 7 18 6 3 16
Cerebellitis 33 11 33 12 0 0
Febrile seizure 21 7 21 7 0 0
Dehydration 35 12 35 12 0 0
Severe pain 21 7 14 5 7 37
Coagulation disorder 19 6 16 6 3 16
Kerato-conjunctivitis 11 4 11 4 0 0
Pneumonitis 7 2 6 2 1 5
Parental distress 4 1 4 1 0 0
Congenital VZV infection 3 1 3 1 0 0
Hepatitis 2 1 2 1 0 0
Nephropathy 2 1 2 1 0 0
Other complications 15 5 15 5 0 0
Total 303 100 284 100 19 100
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maternally derived anti-VZV IgG in these cases, an
important factor to be considered when designing a
VZV immunisation strategy [15, 23].
Our data conﬁrm that immunocompetent children
are at risk for severe complications of varicella leading
to hospitalisation and deaths with secondary bacterial
infections, mainly caused by group A beta-haemolytic
streptococci and S. aureus. Of particular note are two
cases of severe meningococcal sepsis which occurred
in one unit during the study period and have been
published elsewhere [21].
The spectrum and outcome of complications in
immunocompromised patients was similar to those in
immunocompetent individuals. This is most likely due to
increased risk awareness and prompt administration of
antivirals, which were administered to all but one of the
immunocompromised patients.
Whereas cost-beneﬁt analyses of varicella immunisa-
tion have been performed in the United States and Ger-
many, such data are not available for Switzerland [2, 8,
13]. The present study provides a reliable basis for the
assessment of the burden of disease and the potential
beneﬁts of a universal varicella immunisation programme
in Switzerland: a considerably high complication rate,
varicella-related long-term sequelae and fatal outcome in
4% and 0.5% of hospitalised patients, respectively, chal-
lenge the preconception of varicella as a benign disease.
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